Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their holdings of Ordinary share American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions rather than consolidated financial performance.
Material Changes
The filing details an increase in ADR holdings for specific directors and connected persons following the re-investment of dividends paid on October 6, 2011. The transactions occurred at a price of $42.79 per ADR. Specific increases include:
- Dr M M Slaoui: 304.940 ADRs
- Dr K Slaoui (Connected Person): 9.021 ADRs
- Mr W C Louv: 204.729 ADRs
- Dr D Pulman: 265.136 ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Verify the dividend reinvestment plan details for the October 6, 2011 payment date.
- Confirm the market price of GSK ADRs on October 6, 2011, against the reported transaction price of $42.79.
- Review the total aggregate holdings of the named directors post-transaction to assess concentration of ownership.
- Check subsequent filings for any further changes in director holdings or related party transactions.